Reported Earlier, MAIA Biotechnology Raises $950k In Private Placement Of 507,364 Common Shares At $1.872/Share
Reported Earlier, MAIA Biotechnology Raises $950k In Private Placement Of 507,364 Common Shares At $1.872/Share
Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.08 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to customary adjustments as set forth in the warrants).
The gross proceeds from the offering are expected to be approximately $950,000, prior to offering expenses payable by the Company. The Company intends to use the net proceeds received from the sale of the Securities to fund manufacturing of THIO for Phase II clinical trials and for working capital.
每一股普通股都与一个认股权证一起提供,认股权证可按每股2.08美元的行使价购买一股普通股,该价格代表在签署最终协议日股票的账面价值或市场价值中的较高者(根据认股权证中规定的惯例调整)。
该次发行的毛收益预计约为950,000美元,不包括公司需支付的发行费用。公司计划使用从证券销售中获得的净收益来资助THIO的第二期临床试验的制造以及用于营运资本。